Skip to main content

Viaken Secures $13 Million in Second Round Funding

NEW YORK, June 25 – Bioinformatics provider Viaken Systems of Gaithersburg, Md., said Monday it has closed $13 million in second-round equity funding. 

Sterling Venture Partners was the lead investor, along with new participating investors MacAndrews & Forbes, Allianz, Schoffstall Ventures, and E-media, and repeat investors Core Capital Partners and Mid-Atlantic Venture Funds. 

Viaken received $3.7 million in its first institutional round of funding in April 2000.

The company said it expects to use the new funding to support expansion of its sales and marketing efforts and its professional services activities, and further invest in its data products business. 

"This round of financing represents an important step in the growth of the company," said Tom Smith, Viaken director and general partner of Mid-Atlantic Venture Funds. "To raise funds in a challenging economic environment from a quality group of investors is validation of the company's strategy.”

Last week, Viaken announced it had hired Michael Provance, formerly of Internet consulting firm US Interactive, to head its global professional services activities. Provance will take over the responsibilities of managing the services group from Stephen Gardner, Viaken's vice president and CTO. Gardner will now concentrate on developing the company’s data products business and its European operations.  

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.